Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01031225 · ClinicalTrials.gov registry record · Phase 2
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
NCT01031225: Completed Phase 2 study, sponsored by Synta Pharmaceuticals.
NCT01031225 is a Phase 2 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 113 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01031225, a Phase 2 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
Study Summary
This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).
Interventions
- DRUG STA 9090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT01031225 record still lists
NCT01031225 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 1 intervention - of which STA 9090 is the first listed.
NCT01031225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01031225 about?
NCT01031225 is a clinical study titled "A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)". This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).
What is the current status of trial NCT01031225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2009-11. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01031225?
The interventions under investigation include: STA 9090 (DRUG).
Who is sponsoring clinical trial NCT01031225?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01031225's enrollment target sits among peer trials
113 631st of 2000 higher than 1,370 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia